TaiMed Biologics Inc’s (中裕新藥) sales of its Trogarzo HIV treatment are forecast to boom this year after the European Commission on Thursday last week approved it to be marketed, the company said yesterday.
The company plans to begin marketing the drug in Germany this year, as the nation has friendly regulations on drug pricing, allowing companies to market products before wholesale prices are finalized, TaiMed chief financial officer Jack Chen (陳怡成) said by telephone.
Company partner Montreal-based Theratechnologies Inc has begun making connections with hospitals and patients in Germany, targeting sales of the drug by the end of this year or at the beginning of next year, Chen said.
Theratechnologies — TaiMed’s exclusive marketing and distribution partner in more than 30 markets, including the US, Canada and the EU — is to negotiate prices with regulatory bodies in Europe, he said.
The European price has been estimated at 30 percent lower than US$118,000 for a year of treatment in the US, he said.
Trogarzo is a fourth-line treatment and a drug that is designed for people with multi-drug resistance, TaiMed said.
The number of people in Europe with HIV/AIDS who are multi-drug resistant, which means they require alternative treatments, is estimated to be between 20,000 and 25,000, Chen said.
TaiMed is to pay US$5 million to US-based Genentech Inc as a milestone payment, as Genentech developed and licensed the antibody ibalizumab (TMB-355), a key ingredient of Trogarzo.
TaiMed posted revenue of NT$283 million (US$9.12 million) in the first half of this year and expects its full-year revenue to reach NT$800 million thanks to stable sales of Trogarzo in the US, Chen said, adding that the company started marketing the drug in the US in April last year.
It reported a non-operating loss of NT$43 million in the first half, due to a drop in the value of its stake in Theratechnologies, Chen said.
Gross margin fell to 17 percent for the first six months due to low production yield at contract manufacturer WuXi Biologics Co (無錫生物製藥), which is responsible for the production of Trogarzo, Chen said, adding that the yield improved in the third quarter.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) last week recorded an increase in the number of shareholders to the highest in almost eight months, despite its share price falling 3.38 percent from the previous week, Taiwan Stock Exchange data released on Saturday showed. As of Friday, TSMC had 1.88 million shareholders, the most since the week of April 25 and an increase of 31,870 from the previous week, the data showed. The number of shareholders jumped despite a drop of NT$50 (US$1.59), or 3.38 percent, in TSMC’s share price from a week earlier to NT$1,430, as investors took profits from their earlier gains
In a high-security Shenzhen laboratory, Chinese scientists have built what Washington has spent years trying to prevent: a prototype of a machine capable of producing the cutting-edge semiconductor chips that power artificial intelligence (AI), smartphones and weapons central to Western military dominance, Reuters has learned. Completed early this year and undergoing testing, the prototype fills nearly an entire factory floor. It was built by a team of former engineers from Dutch semiconductor giant ASML who reverse-engineered the company’s extreme ultraviolet lithography (EUV) machines, according to two people with knowledge of the project. EUV machines sit at the heart of a technological Cold
Taiwan’s long-term economic competitiveness will hinge not only on national champions like Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) but also on the widespread adoption of artificial intelligence (AI) and other emerging technologies, a US-based scholar has said. At a lecture in Taipei on Tuesday, Jeffrey Ding, assistant professor of political science at the George Washington University and author of "Technology and the Rise of Great Powers," argued that historical experience shows that general-purpose technologies (GPTs) — such as electricity, computers and now AI — shape long-term economic advantages through their diffusion across the broader economy. "What really matters is not who pioneers
TAIWAN VALUE CHAIN: Foxtron is to fully own Luxgen following the transaction and it plans to launch a new electric model, the Foxtron Bria, in Taiwan next year Yulon Motor Co (裕隆汽車) yesterday said that its board of directors approved the disposal of its electric vehicle (EV) unit, Luxgen Motor Co (納智捷汽車), to Foxtron Vehicle Technologies Co (鴻華先進) for NT$787.6 million (US$24.98 million). Foxtron, a half-half joint venture between Yulon affiliate Hua-Chuang Automobile Information Technical Center Co (華創車電) and Hon Hai Precision Industry Co (鴻海精密), expects to wrap up the deal in the first quarter of next year. Foxtron would fully own Luxgen following the transaction, including five car distributing companies, outlets and all employees. The deal is subject to the approval of the Fair Trade Commission, Foxtron said. “Foxtron will be
RSS